1. Home
  2. Mandates
  3. Vinge assisted Active Biotech in licensing deal regarding ANYARA

Mandate Vinge assisted Active Biotech in licensing deal regarding ANYARA

October 27, 2016

Vinge has assisted Active Biotech AB (publ.) in entering into a development and licensing agreement with NeoTX Therapeutics Ltd (”NeoTX”) regarding Active Biotech’s investigational compound ANYARA. NeoTX will be responsible for the worldwide clinical development and commercialization of the drug for cancer indications.
 
Vinge’s team consisted of Erik Sjöman and Kristoffer Franzkeit.

Vinge in first place when the transaction year 2020 is summarized
January 07, 2021

Sanctions round-up

Not long time ago sanctions were a rare occurrence which only involved obscure products and countries, and which were decided by the members of the United Nations Security Council. Today, the European Union and, in particular, the United States, impose sanctions and other trade restrictions with high frequency which have the potential to affect any type of transaction. Below you will find a summary of some recent developments.
December 22, 2020

EU Commission criticizes Sweden for its application of the rules on combined transports

 Through a formal notice to Sweden, the European Commission has criticized the inadequate application of Directive 92/106/ECC on common rules for certain forms of combined transport of goods between Member States (the “Combined Transports Directive”). The notice mainly concerns the Swedish Transport Agency's application of the term "nearest suitable railway station"
December 11, 2020